news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

[ In 2023, UCB's global sales will reach 5.3 billion euros. ]

On August 26, multinational pharmaceutical company UCB announced that it would sell its mature product business in China (involving the nervous system and anti-allergy) to Kangqiao Capital and Mubadala Investment Company for US$680 million (approximately RMB 4.926 billion), including five major products: Keppra, Vipat, Upro, Zyrtec, and Ulcer, as well as a production base in Zhuhai.

UCB told the First Financial reporter that as the company's global R&D pipeline is updated and iterated, a series of innovative drugs will be launched in the global market. The company has decided to adjust its strategic focus in China and sell its mature product business in the nervous system and anti-allergy fields to Asia's largest healthcare industry asset management institutions, Kangqiao Capital and Abu Dhabi Mubadala Investment Company. The two parties will establish a new company and carry out large-scale operations.

The products involved in the transaction will have a combined sales of 131 million euros in China in 2023. UCB said that the transaction is still subject to certain closing conditions, including necessary antitrust review and other customary conditions, and is expected to be completed in the fourth quarter of 2024. This agreement will not affect UCB's global financial expectations for 2024. For 2025, it is expected that the adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) will be slightly diluted if the transaction is completed, but will still remain in the range of 30% to 35% of adjusted EBITDA.

UCB is a multinational pharmaceutical company headquartered in Brussels, Belgium. It is listed on the European Stock Exchange and focuses on developing innovative drugs and therapies for the treatment of severe diseases of the immune and nervous systems. The company has been developing in China for 28 years. In 2023, UCB's global sales reached 5.3 billion euros.